Related Experiment Video
Updated: Feb 1, 2026

Enema of Traditional Chinese Medicine for Patients with Severe Acute Pancreatitis
Published on: January 27, 2023
Outcome postponement as a potential patient centred measure of therapeutic benefit: examples in cardiovascular
Pierre Vladimir Ennezat1, Thierry Le Jemtel2, Shona Cosgrove3
1Centre Hospitalier Régional Universitaire Grenoble-Alpes, Service de Cardiologie, Grenoble, France.
Insights
Presenting randomized controlled trial findings as average survival gain offers a clearer understanding of treatment effects compared to traditional metrics. This method aids both patients and physicians in evaluating drug efficacy and clinical trial outcomes.
Area of Science:
- Clinical Trials
- Cardiovascular Medicine
- Medical Statistics
Background:
- The interpretation of randomized controlled trials (RCTs) is significantly influenced by how their results are presented.
- Traditional methods like absolute risk reduction (ARR), number needed to treat (NNT), and relative risk reduction (RRR) or hazard ratio are commonly used.
- These conventional metrics may not always convey the full clinical impact effectively for patient and physician comprehension.
Purpose of the Study:
- To explore average survival gain as an alternative and informative method for presenting RCT findings.
- To assess the utility of outcome postponement in understanding treatment effects in cardiovascular trials.
- To compare the clarity of survival gain with traditional metrics like hazard ratio and RRR.
Main Methods:
- Analysis of recent cardiovascular RCTs involving medications like ezetimibe/simvastatin, evolocumab, canakinumab, ticagrelor, rivaroxaban, ivabradine, sacubitril/valsartan, and transfemoral aortic valve replacement (TAVR).
- Calculation and comparison of average survival gain (outcome postponement) across different cardiovascular interventions.
- Evaluation of the comprehensibility of survival gain versus hazard ratio and RRR.
Main Results:
- Average survival gains varied significantly, from 4.9 days with ticagrelor versus clopidogrel in acute coronary syndrome patients to 117 days of life expectancy with TAVR for severe aortic stenosis.
- These findings demonstrate a wide range of potential benefits when expressed as survival gain.
- The study highlights the potential for survival gain to offer a more intuitive understanding of treatment benefits.
Conclusions:
- Presenting RCT results using average survival gain (outcome postponement) can enhance understanding for both patients and physicians.
- This alternative metric may be more easily grasped than hazard ratios or relative risk reduction.
- Outcome postponement offers a valuable additional measure for evaluating the clinical impact of new drugs and interventions.
Abstract:
Background: The impact of randomised controlled trials (RCTs) depends heavily on the presentation of the findings.Objective: Classically, RCT findings are presented in the form of absolute risk reduction (ARR), number needed to treat (NNT) to prevent one adverse outcome, and relative risk reduction (RRR) or hazard ratio (the most favourable means for drug marketing). However, the estimation of average survival gain (i.e. outcome postponement between a trial intervention and comparator) is an alternative and informative means of presenting the findings of RCTs.Study selection: Recent cardiovascular RCTs evaluating ezetimibe added to simvastatin, evolocumab, canakinumab, ticagrelor, rivaroxaban, ivabradine, LCZ 696 (sacubitril/valsartan), and transfemoral aortic valve replacement are analysed and discussed.Findings: The average survival gains ranged between 4.9 days on a composite end point with ticagrelor versus clopidogrel in randomised patients with acute coronary syndrome and 117 days of life expectancy obtained with TAVR versus standard therapy in patients with severe aortic stenosis deemed ineligible for surgery.Conclusions: Using outcome postponement as an additional measure of treatment effect is likely to be more easily understood than hazard ratio or RRR by both patients and physicians and could help when evaluating drugs.
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Cardiovascular Drugs: Classification based on Therapeutic Indications
Benefits of Self-Esteem
Newton's Third Law: Examples
Free Body Diagrams: Examples
Predicting Reaction Outcomes

